Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses

On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations astatine 2 upcoming technological congresses. Both presentations volition item CNTY-813, Century's iPSC-derived islet replacement therapy programme engineered with Allo-Evasion™ 5.0 for patients with benignant 1 diabetes.

The presentations are scheduled for the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking spot September 28-October 2, 2026 successful Milan, Italy, and the Breakthrough T1D Clinical & Research Congress 2026, taking spot October 9-11, 2026 successful Philadelphia, Pennsylvania. Century said CNTY-813 is designed to alteration durable engraftment without chronic systemic immunosuppression, and the institution is targeting an IND submission successful the 4th fourth of 2026.

On June 9, Century Therapeutics announced caller preclinical information for CNTY-813 astatine the American Diabetes Association Scientific Sessions. In preclinical models, the therapy demonstrated durable glucose power for implicit 8 months and maintained insulin secretion nether allogeneic immune unit without immunosuppression. CEO Brent Pfeiffenberger said the information beforehand the company's lawsuit for a "potentially functional cure" for benignant 1 diabetes, portion noting that the IND submission remains connected way for the 4th fourth of 2026 and archetypal objective information are anticipated successful the 2nd fractional of 2027.

Century Therapeutics, Inc. (NASDAQ:IPSC) develops allogeneic compartment therapies for the attraction of coagulated tumors, hematological malignancies, and autoimmune diseases.

While we admit the imaginable of IPSC arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.